Avid Bioservices Inc (CDMO)

[JamesGMS]

Robert, with respect to the "look-ins" I've only seen the Transcript - from which the following quote is taken.

With that, I will outline a number of upcoming milestones. Regarding our SUNRISE Phase 3 second line non-small cell lung cancer study, on track, we are on track for completing patient enrollment by year end 2015.

We have planned IDMC interim analysis at 33% and 50% of targeted overall survival events as those were reached, with estimated unblinding of the trials to occur approximately near the calendar year end of 2016.

{Note the word “were” above - did he mean to say “were” - past tense - or did he merely misspeak and actually mean “are” reached?}

Also, it sure would be nice to get a concise explanation of the phrase "targeted overall survival events"

Have a nice evening.

James